Quick Answer
Amneal Pharmaceuticals, Inc. reported Long Term Debt of $2.57 billion for the year ending 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +18.7% in Long Term Debt from 2024 to 2025.
- This data is from Amneal Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $2.64 billion | Q1 2019: $2.63 billion | Q2 2019: $2.62 billion | Q3 2019: $2.61 billion | Q1 2020: $2.77 billion | Q2 2020: $2.76 billion | Q3 2020: $2.76 billion | Q1 2021: $2.73 billion | Q2 2021: $2.72 billion | Q3 2021: $2.69 billion | Q1 2022: $2.67 billion | Q2 2022: $2.62 billion | Q3 2022: $2.61 billion | Q1 2023: $2.56 billion | Q2 2023: $2.55 billion | Q3 2023: $2.54 billion | Q1 2024: $2.38 billion | Q2 2024: $2.18 billion | Q3 2024: $2.17 billion | Q1 2025: $2.15 billion | Q2 2025: $2.15 billion | Q3 2025: $2.57 billion.
- Over the full 9 years of available data (2017 to 2025), Amneal Pharmaceuticals, Inc.'s Long Term Debt has grown by 89.3%.
- Historical annual values: Fiscal year 2025: $2.57 billion | Fiscal year 2024: $2.16 billion | Fiscal year 2023: $2.39 billion | Fiscal year 2022: $2.59 billion | Fiscal year 2021: $2.68 billion | Fiscal year 2020: $2.74 billion | Fiscal year 2019: $2.61 billion | Fiscal year 2018: $2.63 billion | Fiscal year 2017: $1.36 billion.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: